Clinical Trial Update: PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 results for Ibrutinib (PCI-32765) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell prolymphocytic leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Kami Maddocks, MD | Conditions: Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-05-21